Project Oncology®-logo

Project Oncology®

ReachMD

Showcasing major breakthroughs in the field, Project Oncology® educates and assists the heroes who dedicate their lives to pioneering new advancements in the war against cancer. Hear from leading oncologists as they discuss essential screening and diagnostic tools, emerging therapies, counseling strategies, and more.

Showcasing major breakthroughs in the field, Project Oncology® educates and assists the heroes who dedicate their lives to pioneering new advancements in the war against cancer. Hear from leading oncologists as they discuss essential screening and diagnostic tools, emerging therapies, counseling strategies, and more.

Location:

Fort Washington, PA

Networks:

ReachMD

Description:

Showcasing major breakthroughs in the field, Project Oncology® educates and assists the heroes who dedicate their lives to pioneering new advancements in the war against cancer. Hear from leading oncologists as they discuss essential screening and diagnostic tools, emerging therapies, counseling strategies, and more.

Language:

English


Episodes

Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

9/28/2020
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Guest: Josep Tabernero, MD, PhD Dr. Scott Kopetz, Prof. Eric Van Cutsem, and Dr. Josep Tabernero engage in a panel discussion with a focus on the practice-changing initial and subsequently updated mature findings from the BEACON trial. These pivotal findings alter the standard of care for patients with BRAF V600E-mutated metastatic colorectal cancer following first-line failure. Find out what you need to know about the...

Latest Clinical Advances in the Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer

9/28/2020
Host: Scott Kopetz, MD, PhD Guest: Prof Eric Van Cutsem, MD, PhD Dr. Scott Kopetz and Prof. Eric Van Cutsem evaluate both the initial and updated pivotal outcomes from the BEACON trial in second- and third-line BRAF V600E-mutated metastatic colorectal cancer. They extend their discussion of these practice-changing results to include the early-stage findings from the ANCHOR trial in the first-line setting. This podcast also highlights the central role of anti-EGFR therapies in the...

Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

9/21/2020
Host: Richard T. Penson, MD, MRCP Guest: Linda R. Duska, MD, MPH There remains a critical unmet need for effective therapies following the recurrence of endometrial cancer. In this activity, Drs. Linda Duska and Richard Penson assess the role of immunotherapy and targeted therapies in managing advanced endometrial cancers, as well as the importance of evaluating the microsatellite and mismatch repair biomarker status of recurrent and metastatic endometrial cancer.

Keeping Pace: Advances in RET Fusion-Positive NSCLC

8/24/2020
Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted...

Duration:00:12:29

Clinical Considerations for Targeted Therapies Across Multiple Tumor Types

8/21/2020
Host: Sara Hurvitz, MD Guest: Jacob Sands, MD Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob M. Sands discuss the rationale for incorporating the various anti-HER2 therapies in the clinic, and with the use of 3D animation address the...

Duration:00:17:29

Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC

8/7/2020
Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.

Duration:00:11:59

Keeping Pace: The Use of Immunotherapy in Mutation-Positive Non-Small Cell Lung Cancer

7/15/2020
Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive...

Duration:00:14:59

Perspectives for Clinical Practice: The Latest Advances for HER2-positive Metastatic Breast Cancer

7/15/2020
Host: William J. Gradishar MD, FASCO, FACP Guest: Peter Schmid, FRCP, MD, PhD This activity will enhance knowledge and competence in the management of HER2-positive breast cancer. Dr. William Gradishar and Dr. Peter Schmid engage in a lively discussion regarding the latest clinical data supporting novel investigational and approved therapies for the treatment of HER2-positive metastatic breast cancer. They also review strategies to manage adverse events associated with these therapies.

Duration:00:16:59

Keeping Pace: The Role of Immunotherapy After Disease Progression

7/14/2020
Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.

Duration:00:10:59

Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer

6/29/2020
Host: Warner K. Huh, MD Guest: Deborah K. Armstrong, MD Guest: Robert L. Coleman, MD, FACOG, FACS The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy. This activity will discuss recent clinical trials and look at the paradigm shift with PARP inhibitors, specifically within the frontline setting. Also...

Duration:00:13:29

Keeping Pace: The Role of Immunotherapy in the Frontline Setting

6/29/2020
Host: Mark A. Socinski, MD Guest: Suresh S. Ramalingam, MD While advanced non-small cell lung cancer remains incurable, innovations in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This activity will discuss the new scientific and clinical data that have rapidly emerged on immunotherapies in the frontline setting that are leading to changes in the standard of care. Find out how...

Duration:00:13:59

Addressing Unmet Needs in Triage Options During Cervical Cancer Screening

6/25/2020
Host: Stephen M. Cohen, MD, FACOG Guest: Thomas C. Wright, Jr., MD Cervical cancer screening (CCS) methods include cytology alone, use of primary high-risk HPV testing alone, and co-testing. Regardless of the screening approach used, effective triage tests are needed to decide who among the presumptive positive women should receive further diagnostic evaluation. Unfortunately, current approaches to triage can complicate matters and the results can be more confusing than constructive. Our...

Duration:00:14:59

Keeping Pace: Emerging Treatment Considerations in Metastatic Urothelial Cancer

4/10/2020
Host: Peter H. O'Donnell, MD Guest: Daniel P. Petrylak, MD The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with...

Duration:00:13:29

Emerging Treatment Considerations in Metastatic Urothelial Cancer

4/10/2020
Host: Peter H. O'Donnell, MD Guest: Daniel P. Petrylak, MD The treatment of urothelial carcinoma, the most common type of bladder cancer, has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with...

Duration:00:13:29

Emerging Treatment Considerations in Metastatic Urothelial Cancer

4/7/2020
Host: Peter H. O'Donnell, MD Guest: Daniel P. Petrylak, MD The treatment of urothelial cancer has historically been limited to platinum-based chemotherapy; however, the majority of patients will relapse. And while immunotherapy has offered survival benefits to patients, not all patients respond to immune checkpoint inhibitors. That’s why it’s so important for clinicians to understand the current and emerging treatment strategies for patients with metastatic urothelial cancer, as this...

Duration:00:12:59

Current & Future Innovations in Lung Cancer Detection

3/30/2020
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD One of the biggest blindspots for those who care for patients with lung cancer is not knowing whose disease is going to metastasize quickly and who, by extension, would benefit from the most aggressive treatments up front. But the entrance of better detection methods, such as biomarkers and assay tests, could change all of that, as Dr. Tony Hu explains.

Duration:00:13:29

Investigating a Potential Serum Biomarker for Lung Cancer

3/30/2020
Host: Paul Doghramji, MD Guest: Tony Y. Hu, PhD Since treatment outcomes vary greatly between lung cancer patients—even among those who are diagnosed at the same stages of disease—much research has been devoted to finding biomarkers that identify patients who are most likely to develop metastatic disease. Here to walk us through a promising line of research with hopes of adding the first serum biomarker to the fight against non-small cell lung cancer is Dr. Tony Hu, professor and...

Duration:00:09:59

NSCLC State of the Union: Where We Are & Where We're Going

3/30/2020
Guest: Amit Bobby Mahajan, MD, FCCP, DAABIP Lung cancer is known to be the deadliest and second most common cancer in men and women. Although there currently isn’t a cure, the last decade has shown great improvements and hope for the treatment of non-small cell lung cancer, as Dr. Bobby Mahajan explains.

Duration:00:02:59

HIPEC: A Novel Treatment for Advanced Abdominal Cancers

1/23/2020
Host: John J. Russell, MD Guest: Nabil Wasif, MD Image: Mayo Foundation For Medical Education and Research. All Rights Reserved. Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the...

Duration:00:11:59

Best Practices for Curative-Intent Concurrent Chemoradiation Therapy in Unresectable Stage III NSCLC

1/13/2020
Host: Jennifer Caudle, DO Guest: Kristin Higgins, MD Concurrent chemoradiation therapy is the recommended treatment for unresectable Stage III NSCLC patients. Dr. Jennifer Caudle is joined by Dr. Kristin Higgins to discuss advances in radiation that optimize the treatment plan and her best practices to help patients receive a full course of curative-intent treatment. US-32345 Last Updated 12/19

Duration:00:05:29